NJ10 18-0006 (Prevention and treatment of chikungunya virus) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study drug, SAR440894, is safe for the prevention and treatment of chikungunya virus.

What is the Condition Being Studied?

Chikungunya Virus

Who Can Participate in the Study?

Healthy Adults, 18 – 45 who:
-Do not have medical problems
-Do not smoke or use nicotine products
-Do not have a history of cancer (exception: basal cell)
-Do not take prescription medication
-Do not consume excessive caffeine (ex. 4 or more cups of coffee daily)

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Have a physical exam
-Get an electrocardiogram (ECG)
-Give blood and urine samples
-Stay 4 nights in the clinic
- Be randomly assigned (a fair 50/50 chance) to get study drug or placebo (a harmless inactive substance)
-Complete 8 follow-up visits over 5 months

For more information about this study and other clinical research opportunities,
please sign up for our registry here: https://volunteer.dcru.org/p1vw/ Survey and we will contact you.

Study Details

Full Title
A Phase 1, Randomized, Double-Blind, Single Center, Single Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of SAR440894 vs Placebo in Healthy Adults
Principal Investigator
Protocol Number
IRB: PRO00103314
NCT: NCT04441905
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698